Apitope

Apitope is a clinical-stage biotechnology company focused on developing antigen-specific immunotherapies for autoimmune diseases. Apitope utilizes its novel, proprietary discovery platform to select and develop highly specific peptide-based therapies, known as "Apitopes®" (Antigen Processing Independent Epitopes). The mechanism of action and platform of Apitopes® hold broad potential for treating various autoimmune diseases. Current treatments for autoimmune diseases often carry adverse effects associated with immune system suppression, whereas Apitopes® modulate only the defective part of the immune system, avoiding systemic immunosuppression. Apitope was founded in 2002 by Professor David Wraith of the University of Birmingham, UK, and its headquarters is located in Diepenbeek, Belgium.